Breaking News Instant updates and real-time market news.


Chardan Healthcare




Chardan Healthcare signs merger agreement with BiomX

Chardan Healthcare has entered into a definitive agreement for a business combination with BiomX, a microbiome company developing both natural and engineered phage therapies. Assuming no redemption of CHAC shareholders, the combined company will have an initial market capitalization of approximately $254M. Upon closing of the transaction, it is expected that CHAC will be renamed BiomX and remain on the NYSE under a new ticker symbol. CHAC has entered into a mix of commitments including purchase and sale, backstop, and voting agreements with BiomX and with investors so that the $50M minimum closing condition for the transaction has been satisfied. Proceeds from the transaction will provide BiomX with growth capital and the flexibility of a public listing to further accelerate BiomX's expansion as a microbiome product discovery company. BiomX is developing customized phage-based products designed to improve the appearance of acne-prone skin and eradicate harmful bacteria in chronic diseases.


Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.